RxDoctor Payments Data

George Chu, MD

Internal Medicine · Germantown, TNNPI 1467562678

Payments from drug & device makers

$4,696in general payments, 2019–2025

Across 260 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$808
  • Tosoh Bioscience, Inc.$526
  • Amgen$366
  • Boehringer Ingelheim$262
  • Amarin Pharma, Inc.$239
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$4,16389%
  • Education$70%
  • Gifts$52611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,696 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$281,304
Medicare patients
446
Services billed
8,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide46$61,572
JardianceEmpagliflozin55$46,030
FarxigaDapagliflozin Propanediol35$28,002
OzempicSemaglutide22$20,960
TrulicityDulaglutide17$17,705
Janumet XrSitagliptin Phos/Metformin Hcl23$17,650
MyrbetriqMirabegron18$13,147
EliquisApixaban16$9,039
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,655
Hysingla ErHydrocodone Bitartrate12$6,234
SynthroidLevothyroxine Sodium49$6,069
Breo ElliptaFluticasone/Vilanterol14$4,767
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm17$4,062
Atorvastatin Calcium261$2,587
Celecoxib32$2,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$137$80,42380 claims
Boehringer IngelheimJardiance$262$46,03055 claims
AstraZenecaFarxiga$808$28,00235 claims
Novo NordiskOzempic$1,115$20,96022 claims
MerckJanumet Xr$27$17,65023 claims
GSKTrelegy Ellipta, Breo Ellipta$47$12,42326 claims
PfizerEliquis$131$9,03916 claims
AbbVieSynthroid$237$6,06949 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →